ARTICLE | Clinical News
ANB019: Ph I started
April 11, 2017 7:38 PM UTC
AnaptysBio began a double-blind, placebo-controlled, Australian Phase I trial to evaluate subcutaneous and IV ANB019 in 72 healthy volunteers and 15 patients with plaque psoriasis. Volunteers will rec...
BCIQ Company Profiles
BCIQ Target Profiles